Chronic Pancreatitis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Chronic Pancreatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Pancreatitis: Overview
Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance. Chronic pancreatitis is usually a complication of recurrent episodes of acute pancreatitis. Diagnosis of chronic pancreatitis is based on medical history, physical examination, and through various tests like imaging tests, endoscopic retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography. Treatment for chronic pancreatitis includes medical, endoscopic and surgical therapy. Pancreatic enzyme supplementation may be helpful in reducing pain.
'Chronic Pancreatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pancreatitis pipeline landscape is provided which includes the disease overview and Chronic Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Pancreatitis Emerging Drugs
Further product details are provided in the report……..
Chronic Pancreatitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:
Chronic Pancreatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Pancreatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pancreatitis drugs.
Chronic Pancreatitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Pancreatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Pancreatitis: Overview
Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance. Chronic pancreatitis is usually a complication of recurrent episodes of acute pancreatitis. Diagnosis of chronic pancreatitis is based on medical history, physical examination, and through various tests like imaging tests, endoscopic retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography. Treatment for chronic pancreatitis includes medical, endoscopic and surgical therapy. Pancreatic enzyme supplementation may be helpful in reducing pain.
'Chronic Pancreatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pancreatitis pipeline landscape is provided which includes the disease overview and Chronic Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pancreatitis.
This segment of the Chronic Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Pancreatitis Emerging Drugs
- Oral CRAC channel inhibitors: CalciMedica
- NI-03: Kangen Pharmaceuticals
Further product details are provided in the report……..
Chronic Pancreatitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Pancreatitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Pancreatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Pancreatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pancreatitis drugs.
Chronic Pancreatitis Report Insights
- Chronic Pancreatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Pancreatitis drugs?
- How many Chronic Pancreatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pancreatitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pancreatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Pancreatitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- CalciMedica
- GNT Pharma
- Koligo Therapeutics
- Kangen Pharmaceuticals
- AzurRx SAS
- Theraly Fibrosis
- Oral CRAC inhibitor
- Flusalazine
- KT CP 203
- NI-03
- MS1819-SD
- TLY012
Introduction
Executive Summary
Chronic Pancreatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Pancreatitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MS1819-SD: AzurRx SAS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Flusalazine: GNT Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Oral CRAC inhibitor: CalciMedica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Pancreatitis Key Companies
Chronic Pancreatitis Key Products
Chronic Pancreatitis- Unmet Needs
Chronic Pancreatitis- Market Drivers and Barriers
Chronic Pancreatitis- Future Perspectives and Conclusion
Chronic Pancreatitis Analyst Views
Chronic Pancreatitis Key Companies
Appendix
Executive Summary
Chronic Pancreatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Pancreatitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MS1819-SD: AzurRx SAS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Flusalazine: GNT Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Oral CRAC inhibitor: CalciMedica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Pancreatitis Key Companies
Chronic Pancreatitis Key Products
Chronic Pancreatitis- Unmet Needs
Chronic Pancreatitis- Market Drivers and Barriers
Chronic Pancreatitis- Future Perspectives and Conclusion
Chronic Pancreatitis Analyst Views
Chronic Pancreatitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Pancreatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Pancreatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Pancreatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Pancreatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
